ABSTRACT
Background Estimates of prevalence of anti-SARS-CoV-2 antibody positivity (seroprevalence) are for tracking the Covid-19 epidemic and are lacking for most African countries.
Objectives To determine the prevalence of antibodies against SARS-CoV2 in a sentinel cohort of patient samples received for routine testing at tertiary laboratories in Johannesburg, South Africa
Methods This sentinel study was conducted using remnant serum samples received at three National Health Laboratory Services laboratories situated in the City of Johannesburg (COJ) district, South Africa. Collection was from 1 August until the 31 October 2020. We extracted accompanying laboratory results for haemoglobin A1c, creatinine, HIV, viral load, and CD4+ T cell count. An anti-SARS -CoV-2 targeting the nucleocapsid (N) protein of the coronavirus with higher affinity for IgM and IgG antibodies was used. We reported crude as well as population weighted and test adjusted seroprevalence. Multivariate logistic regression method was used to determine if age, sex, HIV and diabetic status were associated with increased risk for seropositivity.
Results A total of 6477 samples were analysed; the majority (5290) from the COJ region. After excluding samples with no age or sex stated, the model population weighted and test adjusted seroprevalence for COJ (N=4393) was 27.0 % (95% CI: 25.4-28.6%). Seroprevalence was highest in those aged 45-49 [29.8% (95% CI: 25.5-35.0 %)] and in those from the most densely populated areas of COJ. Risk for seropositivity was highest in those aged 18-49 as well as samples from diabetics (aOR =1.52; 95% CI: 1.13-2.13; p=0.0005) and (aOR=1.36; 95% CI: 1.13-1.63; p=0.001) respectively.
Conclusion Our study conducted during the first wave of the pandemic shows high levels of infection among patients attending public health facilities in Gauteng.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Health Laboratory Services, South Africa
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
"The study was approved by the University of the Witwatersrand Human Ethics Committee (certificate number M2008105)."
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
JAG, IM & NC: Formal analysis and Visualization.
All authors: Conceptualization, Writing – Original Draft Preparation, Writing – Review, Editing and Methodology and Resources.
Data Availability
Data available subject to approval by instututional ethics committee
